Airway mechanics after withdrawal of a leukotriene receptor antagonist in children with mild persistent asthma : Double-blind, randomized, cross-over study
© 2020 Wiley Periodicals LLC..
BACKGROUND: To determine the response of airway mechanics and the changes in asthma symptoms to stepping down of leukotriene receptor antagonist (LTRA) therapy.
METHODS: Thirty children (mean age: 7.1 years) with mild, well-controlled, and persistent asthma who took LTRA as maintenance treatment were randomized into a double-blind, placebo-controlled, cross-over study. Each group received an LTRA (montelukast) or placebo daily for 2 weeks, followed by a 1-week washout period, and then the alternate treatment for 2 weeks. Spirometry and impulse oscillation system (IOS) measurements before and after four puffs of salbutamol inhalation, fractional exhaled nitric oxide (FeNO), and the childhood asthma control test (C-ACT) were evaluated at baseline, the end of placebo treatment, and the end of LTRA treatment.
RESULTS: Changes of FEV1 /FVC (p = .113) and FEV1 (p = .109) from baseline to posttreatment did not differ significantly between the placebo and montelukast groups. In the placebo group, prebronchodilator (pre-) FEV1 /FVC was decreased (83% vs. 86%) and bronchodilator response (BDR) in FEV1 was diminished (10.7% vs. 6.4%) at posttreatment compared with baseline. However, the montelukast group had no significant changes in pre-FEV1 /FVC (p = .865) and BDR in FEV1 (p = .461). In addition, compared with the montelukast group, the placebo group showed no significant changes in Rrs5 (total airway resistance), Rrs5-20 (peripheral airway resistance), FeNO, and symptoms by the C-ACT.
CONCLUSION: In children with well-controlled mild persistent asthma, changes in spirometry, IOS, FeNO, and C-ACT results did not differ between the placebo and montelukast groups within 2 weeks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Pediatric pulmonology - 55(2020), 12 vom: 04. Dez., Seite 3279-3286 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Ju Hee [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.03.2021 Date Revised 17.03.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ppul.25085 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315369140 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315369140 | ||
| 003 | DE-627 | ||
| 005 | 20231225154751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ppul.25085 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315369140 | ||
| 035 | |a (NLM)32965787 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Ju Hee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Airway mechanics after withdrawal of a leukotriene receptor antagonist in children with mild persistent asthma |b Double-blind, randomized, cross-over study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.03.2021 | ||
| 500 | |a Date Revised 17.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: To determine the response of airway mechanics and the changes in asthma symptoms to stepping down of leukotriene receptor antagonist (LTRA) therapy | ||
| 520 | |a METHODS: Thirty children (mean age: 7.1 years) with mild, well-controlled, and persistent asthma who took LTRA as maintenance treatment were randomized into a double-blind, placebo-controlled, cross-over study. Each group received an LTRA (montelukast) or placebo daily for 2 weeks, followed by a 1-week washout period, and then the alternate treatment for 2 weeks. Spirometry and impulse oscillation system (IOS) measurements before and after four puffs of salbutamol inhalation, fractional exhaled nitric oxide (FeNO), and the childhood asthma control test (C-ACT) were evaluated at baseline, the end of placebo treatment, and the end of LTRA treatment | ||
| 520 | |a RESULTS: Changes of FEV1 /FVC (p = .113) and FEV1 (p = .109) from baseline to posttreatment did not differ significantly between the placebo and montelukast groups. In the placebo group, prebronchodilator (pre-) FEV1 /FVC was decreased (83% vs. 86%) and bronchodilator response (BDR) in FEV1 was diminished (10.7% vs. 6.4%) at posttreatment compared with baseline. However, the montelukast group had no significant changes in pre-FEV1 /FVC (p = .865) and BDR in FEV1 (p = .461). In addition, compared with the montelukast group, the placebo group showed no significant changes in Rrs5 (total airway resistance), Rrs5-20 (peripheral airway resistance), FeNO, and symptoms by the C-ACT | ||
| 520 | |a CONCLUSION: In children with well-controlled mild persistent asthma, changes in spirometry, IOS, FeNO, and C-ACT results did not differ between the placebo and montelukast groups within 2 weeks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a FeNO | |
| 650 | 4 | |a IOS | |
| 650 | 4 | |a bronchodilator response | |
| 650 | 4 | |a leukotriene receptor antagonist | |
| 650 | 4 | |a montelukast | |
| 650 | 4 | |a small airway dysfunction | |
| 650 | 4 | |a spirometry | |
| 650 | 7 | |a Acetates |2 NLM | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 650 | 7 | |a Cyclopropanes |2 NLM | |
| 650 | 7 | |a Leukotriene Antagonists |2 NLM | |
| 650 | 7 | |a Quinolines |2 NLM | |
| 650 | 7 | |a Sulfides |2 NLM | |
| 650 | 7 | |a Nitric Oxide |2 NLM | |
| 650 | 7 | |a 31C4KY9ESH |2 NLM | |
| 650 | 7 | |a montelukast |2 NLM | |
| 650 | 7 | |a MHM278SD3E |2 NLM | |
| 650 | 7 | |a Albuterol |2 NLM | |
| 650 | 7 | |a QF8SVZ843E |2 NLM | |
| 700 | 1 | |a Lee, Shinhae |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Youn Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Ha, Eun Kyo |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Seung Won |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Mi-Ae |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Jung Won |e verfasserin |4 aut | |
| 700 | 1 | |a Baek, Hey Sung |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Sun-Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Man Yong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric pulmonology |d 1993 |g 55(2020), 12 vom: 04. Dez., Seite 3279-3286 |w (DE-627)NLM012888230 |x 1099-0496 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2020 |g number:12 |g day:04 |g month:12 |g pages:3279-3286 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ppul.25085 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2020 |e 12 |b 04 |c 12 |h 3279-3286 | ||